Indeed, reduced production of mucosal-barrier-related molecules, such as antimicrobial peptides and MUC2, with goblet cell loss and barrier dysfunction was observed in the intestinal lesions of IBD patients [14,15,37]. Here, MUC2 is linked to inflammatory bowel disease.